Wesana Health Holdings Inc. (WSNAF)
USD 0.04
(135.29%)
USD 0.04
(135.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 987.96 Thousand USD | -48.92% |
| 2022 | 1.93 Million USD | -80.15% |
| 2021 | 9.74 Million USD | 668.69% |
| 2020 | 1.26 Million USD | 338.74% |
| 2019 | 288.85 Thousand USD | -29.79% |
| 2018 | 411.41 Thousand USD | 4735.08% |
| 2017 | 8508.91 USD | 19.98% |
| 2016 | 7092.08 USD | -82.96% |
| 2015 | 41.62 Thousand USD | -82.42% |
| 2014 | 236.81 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 506.77 Thousand USD | -31.55% |
| 2024 Q1 | 740.5 Thousand USD | -25.05% |
| 2023 Q4 | 987.96 Thousand USD | -40.35% |
| 2023 Q2 | 1.57 Million USD | -13.96% |
| 2023 Q3 | 1.65 Million USD | 4.96% |
| 2023 Q1 | 1.83 Million USD | -5.19% |
| 2023 FY | 987.96 Thousand USD | -48.92% |
| 2022 Q2 | 5.14 Million USD | -21.78% |
| 2022 FY | 1.93 Million USD | -80.15% |
| 2022 Q4 | 1.93 Million USD | -20.17% |
| 2022 Q3 | 2.42 Million USD | -52.91% |
| 2022 Q1 | 6.57 Million USD | -32.48% |
| 2021 FY | 9.74 Million USD | 668.69% |
| 2021 Q3 | 36.28 Million USD | 155.4% |
| 2021 Q4 | 9.74 Million USD | -73.15% |
| 2021 Q2 | 14.2 Million USD | 363.66% |
| 2021 Q1 | 3.06 Million USD | 141.78% |
| 2020 FY | 1.26 Million USD | 338.74% |
| 2020 Q4 | 1.26 Million USD | 0.0% |
| 2019 FY | 288.85 Thousand USD | -29.79% |
| 2018 FY | 411.41 Thousand USD | 4735.08% |
| 2017 FY | 8508.91 USD | 19.98% |
| 2016 FY | 7092.08 USD | -82.96% |
| 2015 FY | 41.62 Thousand USD | -82.42% |
| 2014 FY | 236.81 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -42669.134% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 49.547% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 90.639% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -78.941% |
| Rebus Holdings, Inc. | 5000.00 USD | -19659.34% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.241% |
| Qrons Inc. | 420.00 USD | -235130.238% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -28.2% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 96.464% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -105.588% |
| Skye Bioscience, Inc. | 11.94 Million USD | 91.726% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 97.457% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 86.316% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1193.93% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.078% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 31.009% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1265.255% |
| Mesoblast Limited | 667.9 Million USD | 99.852% |
| Marizyme, Inc. | 22.01 Million USD | 95.512% |
| Genus plc | 1.02 Billion USD | 99.904% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 27.267% |
| Pharming Group N.V. | 462.85 Million USD | 99.787% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 70.179% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -97.974% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -57.57% |
| ContraFect Corporation | 20.67 Million USD | 95.222% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -153.087% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -158.51% |
| IMV Inc. | 31.33 Million USD | 96.847% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 76.171% |
| MultiCell Technologies, Inc. | 126.22 USD | -782634.115% |
| ONE Bio Corp. | 70.08 Million USD | 98.59% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -5.138% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.231% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -128.848% |
| Q BioMed Inc. | 3.51 Million USD | 71.897% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 97.192% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -278.13% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1238.364% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.779% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 31.81% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 96.708% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 64.026% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -43.707% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 62.048% |
| GB Sciences, Inc. | 103.44 Thousand USD | -855.093% |
| Alpha Cognition Inc. | 2.45 Million USD | 59.711% |
| HST Global, Inc. | 1526.00 USD | -64642.267% |
| CSL Limited | 38.02 Billion USD | 99.997% |
| Halberd Corporation | 10.13 Thousand USD | -9651.92% |
| Enzolytics Inc. | 361.7 Million USD | 99.727% |
| Agentix Corp. | 261.39 Thousand USD | -277.964% |
| Resverlogix Corp. | 8.11 Million USD | 87.825% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 47.389% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.978% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 97.929% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -54.453% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -4236.803% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 88.96% |
| AVAX Technologies, Inc. | 7.37 Million USD | 86.608% |
| Zenith Capital Corp. | 7410.00 USD | -13232.888% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.971% |
| Ember Therapeutics, Inc. | 184.00 USD | -536838.587% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -207.007% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -278.004% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -6.466% |
| Kadimastem Ltd | 2.3 Million USD | 57.121% |
| Helix BioMedix, Inc. | 3.02 Million USD | 67.341% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.125% |
| BioStem Technologies, Inc. | 14.56 Million USD | 93.215% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1630.422% |
| LadRx Corporation | 2.3 Million USD | 57.192% |
| Cell Source, Inc. | 195.17 Thousand USD | -406.206% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -179.389% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -179.389% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1487.147% |
| Affymax, Inc. | 7.44 Million USD | 86.726% |
| Itoco Inc. | 1.4 Million USD | 29.435% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -932.822% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -832.044% |
| Mobile Lads Corp. | 52.00 USD | -1899836.538% |
| CytoDyn Inc. | 11.13 Million USD | 91.128% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -591.021% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -5425.543% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -156.301% |
| SYBLEU INC | 330.46 Thousand USD | -198.96% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -141.308% |
| International Stem Cell Corporation | 5.39 Million USD | 81.67% |
| Bioxytran, Inc. | 137.63 Thousand USD | -617.801% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 93.414% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 94.041% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1150.591% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -14.259% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 86.857% |
| Neutra Corp. | 2851.00 USD | -34553.35% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 96.951% |
| PureTech Health plc | 693.97 Million USD | 99.858% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 87.759% |
| IXICO plc | 15.84 Million USD | 93.764% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 88.071% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.044% |
| CSL Limited | 38.02 Billion USD | 99.997% |
| Cellectis S.A. | 333.99 Million USD | 99.704% |